NCT03773107 2025-01-13LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaWake Forest University Health SciencesPhase 1/2 Completed12 enrolled 19 charts
NCT00639002 2018-02-13A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaIncyte CorporationPhase 2 Completed13 enrolled 7 charts